BLIOGRAFIA - I Disordini Neurosensoriali nelle Encefalopatie Epilettiche: intervento riabilitativo nelle epilessie miocloniche severe (Sindrome di Dravet)
Ackermann H, Hertrich I. The contribution of the cerebellum to speech processing. J Neurolinguist 2000; 13: 95-116.
Aicardi J. Epilepsy in children (II edition). New York: Raven Press, 1994.
Akiyama M. Kobayashi K. Yoshinaga H, Ohtsuka Y. A long-term follow-up study of Dravet syndrome up to adulthood.
Epilepsia 2010; 51: 1043-52-
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts of the organization of seizures and epilepsies: Report of the ILAE commission on classification and terminology, 2005- Epilepsia 2010; 51: 676-85.
Brodie MJ, Schachter SC, Kwan P. Fast Facts: Epilessia. Fourth edition. Health Press Ltd. 2009
Buoni S, Orrico A, Galli L, et al. SCN1A novel truncating mutation with benign outcome of severe myoclonic epilepsy of infancy. Neurology, 2006; 66: 606.
Bureau M, Dalla Bernardina B. Electroencephalographic characteristics of Dravet Syndrome.
Epilepsia, 2011; 52 (Suppl. 2): 13-23.
Camfield P, Camfield C, Nolan K. Helping families cope with the devastation of Dravet syndrome.
European Journal of Paediatric Neurology 2012; 16: S9-S12.
Caraballo RH, Fejerman N. Dravet syndrome: A study of 53 patients. Epilepsy Res 2006; 70 (Suppl. 1): S231-8.
Caraballo RH. Nonpharmacologic treatments of Dravet syndrome: Focus on the ketogenic diet.
Epilepsia, 2011; 52 (Suppl. 2): 79-82.
Cassé-Perrot C, Woff M, Dravet C. Neuropsychological aspects of severe myoclonic epilepsy in infancy. In: Jamaqué I, Lassonde M, Dulac O (eds). The Neuropsycology of childhood epilepsy. New- York: Plenum Press/Kluwer Accademic 2001; 131-40.
Castro-Gago M, Martinon Sanchez JM, Rodriguez-Nunez A, Herranz Fernandez JL. Eiris-Punal J. Severe Myoclonic epilepsy and mitochondrial cytopathy. Childs Nerv Syst 1997; 13: 570-1.
Catarino et al. Dravet syndrome as epileptic encelophaty: evidence from long-term course and neuropathology. Brain 2011.
Ceulemans B, Boel M, Claes L, et al. Severe myoclonic epilepsy in infancy: towards an optimal treatment. J Child Neurol 2004; 19: 516-21.
Chieffo D, Ricci D, Baranello G, Martinelli D, Veredice C, Lettori D, Battaglia D, Dravet C, Mercuri E, Guzzetta F. Early development in Dravet syndrome; visual function impairment precedes cognitive decline. Epilepsy Research 2010; 93: 73-9.
Chieffo D, Ricci D, Baranello G, et al. Early development in Dravet Syndrome; visual function impairment precedes cognitive decline. Epilepsy Res 2011a; 93: 73-9.
Chieffo D, Battaglia D, Lettori D, et al. Neuropsychological development in children with Dravet Syndrome. Epilepsy Res 2011b; 95: 86-93.
Chiron C, Dulac O. The pharmacologic treatment of Dravet Syndrome. Epilepsia 2011; 52 (Suppl. 2): 72-5.
Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomized placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 11: 356: 1638-42.
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68: 1327-32.
Coppola G, Capovilla G, Montagnini A, et al. Topiramate ad add-on drug in severe myoclonic epilepsy in infancy: An Italian multi center open trial. Epilepsy Res 2002; 49: 45-8.
Dalla Bernardina B, Capovilla G, Gattoni MB, Colamaria V, Bondavalli S, Bureau M. Èpilepsie myoclonique grave de la première année. Rev EEG Neurophysiol 1982; 12: 21-5.
Dalla Bernardina B, Capovilla G,Chiamenti C, Trevisan E, Colamaria V, Fontana E. Cryptogenic myoclonic epilepsies of infancy and early childhood: Nosological and prognostic approach. In: Wolf P, Dam M, Janz D, Dreifuss FE (eds). Advances in Epileptology. New-York: Raven Press, 1987: 175- 80.
Davidsson J, Collin A, Olsson ME, Lundgren J, Soller M. Deletion of the SCN gene cluster on 2q24.4 is associated with severe epilepsy: An array-based genotype-phenotype correlation and a comprehensive review of previously published cases. Epilepsy Res 2008; 81: 69-79.
Delogu AB, Spinelli A, Battaglia D, et al. Electrical and autonomic cardiac function in patients affected by Dravet syndrome. Epilepsia 2011; 52 (Suppl. 2): 55-8.
Depienne C, Arzimanoglou A, Trouillard O, et al. Parental mosaicism can cause recurrent transmission of SCN1A mutation associated with severe myoclonic epilepsy of infancy. Hum Mutat 2006; 27: 389.
Depienne C, Trouillard O, Gourfinkel-An I, et al. Mechanism for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. J Med Genet 2010; 47: 404-10.
Dibbens LM, Tarpey PS, Hynes K, et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet 2008; 40: 776-81.
Donner EJ, Smith CR, Snead OC. Sudden unexplained death in children with epilepsy. Neurology 2001; 57: 430-4.
Dravet C. Les epilepsies graves de l’enfant. Vie Med 1978; 8: 543-8.
Dravet C, Dalla Bernardina B, Mesdjian E, Galland MC, Roger J. Dyskinésies paroxystiques au cours des traitements par la diphénylhydantoine. Rev Neurol 1980; 136: 1-14.
Dravet C, Roger J, Bureau M, Dalla Bernardina B. Myoclonic epilepsies in childhood. In: Akimoto H, et al. (eds). Advances in Epileptology, the XIII EIS. New-York: Raven Press, 1982; 135-40.
Dravet C, Bureau M, Roger J. Severe myoclonic epilepsy in infancy. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Wolf P (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey, 1985; 58-67.
Dravet C & Jallon P. Il bambino con epilessia. 2000 Editore Borla.
Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infants. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence (II edition). London: John Libbey, 1992a; 75-88.
Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet Syndrome). In: Roger J, Bureau M, Dravet C, Gelton P, Tassinari CA, Wolf P (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence (IV edition). Paris: John Libbey Eurotext, 2005a: 89-113.
Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy: Dravet Syndrome. In: Delgado-Escueta AV, Guerrini R, Medina MT, Genton P, Bureau M, Dravet C (eds). Advances in Neurology. Vol. 95. Philadelphia: Lippinvcott Williams & Wilkins, 2005b: 71-102.
Dravet C, Daquin G, Battaglia D. Severe myoclonic epilepsy in infancy (Dravet Syndrome). In: Nikanorova M, Gelton P, Sabers A (eds). Long-term evolution of epileptic encephalopaties. Paris: John Libbey Eurotext, 2009: 29-38.
Dravet C. The core Dravet Syndrome phenotype. Epilepsia 2011; 52 (Suppl.2): 3-9
Dravet C, Guerrini R. Dravet Syndrome. Topics in Epilepsy. John Libbey Eurotext 2011.
Dravet C. Addressing the needs of patients and their family: Conclusion. European Journal of
Paediatric Neurology 2012; 16: S18-S20.
Dulac O, Arthuis M. L’épilepsie myoclonique sévère de l’enfant. In: Journées parisiennes de pédiatrie. Paris: Flammarion, 1982: 259-68.
Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium cannel in two famiglie with GEFS+2. Nat Genet 2000; 24: 343-5.
Fisher JL. The anticonvulsant stiripentol acts directly on the GABAa receptor as a positive allosteric modulator. Neuropharmacology 2009; 56: 190-7.
Fisher JL. Interactions between modulators of the GABAa receptor: Stiripentol and benzodiazepines.
Eur J Pharmaco 2011a; 2: 160-5.
Fisher JL. The effects of stiripentol on GABAa receptors, Epilepsia 2011b; 52 (Suppl. 2): 76-8. Fontana E, Dalla Bernardina B, Sgrò V, et al. Epilessia mioclonica severa (EMS) e/o Sindrome di
Dravet: Studio elettroclinico longitudinale di 53 soggetti. Boll Lega It Epil 2004; 125/126: 337-40.
Fujiwara T, Nakamura H, Watanabe M, et al. Clinicoelectrographic concordance between monozygotic twins with severe myoclonic epilepsy in infancy. Epilepsia 1990; 31: 281-6.
Fujiwara T, Watanabe M, Takahashi Y, et al. Long-term course if childhood epilepsy with intractable
Grand Mal seizures. Jpn J Psychiatr Neurol 1992; 46: 29.
Fujiwara T, Suguwara T, Mazaki-Miyazaki E, et al. Mutations of sodium canne alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003; 126: 531-46.
Fukuma G, Ognuni H, Shirasaka Y, et al. Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia 2004; 45: 140-8.
Gastaut H, Broughton R, Tassinari CA. Unilateral epileptic seizures. In: Vinken PJ, Bruyn GW (eds). Handbook of Clinical Neurology: The Epilepsies, Vol XV. Amsterdam/New-York: Elsevier, 1974: 235-45.
Gennaro E, Santorelli FM, Bertini E, et al. Somatic and germiline mosaicism in Severe myoclonic epilepsy of infancy. Biochem Biophysl Res Commun 2006; 341: 489-93.
Genton P, Velizarova R, Dravet C. Dravet syndrome: The long-term outcome. Epilepsia 2011; 52 (Suppl. 2): 44-9.
Giobbi G, Giovanni S, Boni A, Visconti P, Beghi M, Cornaggia CM. Catatonic psychosis related to forced normalization in a girl with Dravet’s syndrome. Epileptic Disord 2008; 10: 125-9.
Giovanardi-Rossi PR, Santucci M, Gobbi G, Parmeggiani A, Pini A, Ambrosetto G. Long-term follow-up of severe myoclonic epilepsy in infancy. In: Fukuyama Y, Kamoshita S, Ohtsuka C, Susuki Y (eds). Modern perspectives of child neurology. Tokyo: Asahi Daily News, 1991: 205-13.
Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 2006; 34: 608-11.
Granata T. Comprehensive care of children with Dravet syndrome. Epilepsia 2011; 52 (Suppl. 2): 90- 4.
Grosso S, Galimberti D, Farnetani MA, et al. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 2005; 14: 183-9.
Grusser Cornehls U, Baurle J. Mutant mica as a model for cerebellar ataxia. Progr Neurobiol 2001; 63: 489-540.
Guerrini R, Falchi M. Dravet syndrome and SCN1A gene mutation related-epilepsies: Cognitive impairment and its determinants. Dev Med Child Neurol 2011; 53 (Suppl. 2): 11-5.
Guerrini R, Oguni H. Borderline Dravet syndrome: A useful diagnostic category? Epilepsia 2011a; 52 (Suppl. 2): 10-2.
Guerrini R, Pons G (eds). Comparative Study of the Efficacy of Stiripentol used in Combination in Severe Myoclonic Epilepsy of Infancy (SMEI). A Double-Blind, Multicenter, Placebo-Controlled Phase III Study. Calabrone (Pisa), Italy: Università di Pisa-IRCCS Stella Maris, 2000.
Guerrini R, Dravet C, Genton P, Bureau M, Bonanni P, Ferrari AR, Roger J. Idiopathic photosensitive occipital lobe epilepsy. Epilepsia 1995b; 36 (9): 883-91.
Guerrini R, Dravet C, Gelton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-12.
Guerrini R, Tonnelier S, D’Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): A placebo-controlled trial. Epilepsia 2002; 43 (Suppl. 9): S155.
Guerrini R, Cellini E, Mei D, et al. Variable epilepsy phenotypes associated with a familiar intragenic deletion of SCN1A gene. Epilepsia 2010; 51: 2474-7.
Guerrini R, Striano P, Catarino C, Sisodiya SM. Neuroimaging and neuropathy of Dravet syndrome.
Epilepsia 2011b; 52 (Suppl. 2): 30-4.
Guerrini R. Dravet Syndrome: The main issues. European Journal of Paediatric Neurology 2012; 16: S1-S4.
Guzzetta F, Cioni G, Mercuri E, et al. Neurodevelopmental evolution of West syndrome: A 2-year prospective study. Eur J Paediatr Neurol 2008; 12: 387-97.
Harkin LA, Bowser DN, Dibbens LM, et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 2002; 70: 530-53.
Hattori J, Ouchida M, Ono J, et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia 2008; 49: 626-33.
Hino-Fukuyo N, Haginoya K, Togashi N, et al. Ictal vomiting a san initial symptom of Severe myoclonic epilepsy in infancy: A case report. J Child Neurol 2009; 24: 228.
Horn CS, Ater SB, Hust DL. Carbamazepine-exacerbated epilepsy in children and adolescents.
Pediatr Neurol 1986; 2: 340-5.
Hurst DL. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia 1990; 31: 397-400. Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res 2009; 85: 89-95.
Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet Syndrome. Epilepsia 2009; 50: 2362-8.
Jansen FE, Sadleir LG, Harkin LA, et al. Severe myoclonic epilepsy of infancy (Dravet syndrome): Recognition and diagnosis in adults. Neurology 2006; 67: 224-6.
Justus T, Ravizza SM, Fiez JA, Ivry RB. Reduced phonological similarity effects in patients with damage to the cerebellum. Brain Lang 2005; 95: 304-18.
Kalume F, Yu FH, Westenbroek RE, Scheure T, Catterall WA. Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications of ataxia in severe myoclonic epilepsy in infancy. J Neurosci 2007; 27: 1165-74.
Kanazawa O. Medically intractable generalized tonic-clonic or clonic seizures in infancy. J Epil 1992; 5: 143-8.
Kanazawa O, Shirane S. Can early zonizamide medication improve the prognosis in the core and peripheral types of severe myoclonic epilepsy in infants? Brain Dev 1999; 21: 503.
Kassai C, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: A systematic review and meta-analysis of individual parent data. Epilepsia 2008; 49: 343-8.
Korff C, Laux L, Kelley K, Goldstein J, Koh S, Nordli D Jr. Dravet syndrme (severe myoclonic epilepsy in infancy) A retrospective study of 16 patients. J Child Neurosl 2007; 22: 185-94.
Kossof EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009; 50: 304-17.
Krishna-K K, Hertel N, Redies C. Cadherin expression in the somatosensory cortex: Evidence for a combinatorial molecular code at the single-cell level. Neuroscience 2011; 175: 37-48.
Kroll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory parients with
Dravet syndrome. Neuropediatrics 2006; 37: 325-9.
Mangano S, Fontana A, Cusumano L. Begin myoclonic epilepsy in infancy: Neuropsychological and behavioral outcome. Brain Dev 2005; 27: 218-23.
Marini C, Mei D, Cross JH, Guerrini R. Mosaic SCN1A mutation in familial severe myoclonic epilepsy in infancy. Epilepsia 2006; 47: 1737-40.
Marini C, Mei D, Temudo T, et al. Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities. Epilepsia 2007; 48: 1678-96.
Martin MS, Dutt K, Papale LA, et al. Altered function of the SCN1A voltage-gated sodium canne leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Cherm 2010; 285: 9823-34.
McGregor A, Wheeless J. Pediatric experience with sudden unexplained death in epilepsy at the tertiary center. J Child Neurol 2006; 21: 782-7.
Mercuri E, Haataja L, Guzzetta A, et al. Visual function in term infants with hypoxic-ischemic insults correlation with neurodevelopment at 2 years of age. Arch Dis Child Fetal Neonatal Ed 1999; 80: F99-104.
Morimoto M, Mazaki E, Nishimura A, et al. SCN1A mutation mosaicism in a family with severe myoclonic epilepsy in infancy. Epilepsia 2006; 47: 1732-6.
Nabbout R, Gennaro E, Dalla Bernardina B, et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology 2003; 60: 1961-7.
Nabbout R, Desguerre I, Sabbagh S, et al. An unexpected EEG course in Dravet syndrome. Epilepsy Res 2008; 81: 90-5.
Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: A prospective pilot study. Epilepsia 2011; 52: 54-7.
Nakayama T, Ogiwara I, Iti K, et al. Delections of SCN1A 5’ genomic region with promoter activity in Dravet syndrome. Hum Mutat 2010; 31: 820-9.
Nieto M, Roldan S, Sanchez B, et al. Estudio immunologico en pacientes con epilepsia mioclònica severa en la infancia. Rev Neurol (Spanish) 2000; 30: 1-15.
Nieto-Barrera M, Lillo MM, Rodriguez-Collado C, Candau R, Correa A. Epilepsia mioclonica grave de la infancia. Estudio epidemiologico analitico. Rev Neurol (Spanish) 2000a; 30: 620-4.
Nieto-Barrera M, Candau R, Nieto-Jimenez M, Candau R, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000b; 8: 590-4.
Ogino T, Ohtsuka Y, Tamatogi Y, et al. The epileptic syndrome sarin common characteristics during early childhood with severe myoclonic epilepsy in infancy. Jpn J Psychiatry Neurol 1989; 43: 479-81.
Ogiwara I, Miyamoto H, Morita N, et al. Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: A circuit basis for epileptic seizures in mice carrying an SCN1A gene mutation. J Neursci 2007; 27: 5903-14.
Oguni H, Kitami H, Oguni M, et al. Treatment of severe myoclonic epilepsy in infants and its borderline variant with bromide. Epilepsia 1994; 35: 1140-5.
Oguni H, Hayashi K, Awaya Y, Fukuyama Y, Osawa M. Severe myoclonic epilepsy in infants – a rewiew based on the Tokyo Women’s medical university series of 84 cases. Brain Dev 2001; 23: 736- 48.
Oguni H, Hayashi K, Osawa M, et al. Severe myoclonic epilepsy in infants. Typical and borderline groups in relation to SCN1A mutations. In: Delgado-Escueta V, Guerrini R, Medina MT, Gelton P, Bureau M, Dravet C (eds). Advaces in Neurology, vol 95, Myoclonic Epilepsies. Philadelphia: Lippincott Williams & Wilkins, 2005: 103-11.
Ohki T, Watanabe K, Negoro K, et al. Severe myoclonic epilepsy in infancy: Evolution of seizures.
Seizure 1997; 6: 219-24.
Ohmori I, Ohtsuka Y, Murakami N, AsanoT, Hattori J, Oka E. Analysis of ictal EEG in Severe
Ohmori I, Ogtsuka Y, Ouchida M, Ogino T, Maniwa S, Shimizu K, Oka E. Is phenotype difference in severe myoclonic epilepsy in infancy related to SCN1A mutations? Brain Dev 2003; 27: 488-93.
Ohtsuka Y, Ohmori I, Ogino T, Ouchuida M, Shimizu K, Oka E. Paroxysmal movement disorders in severe myoclonic epilepsy in infancy. Brain Dev 2003; 25: 401-5.
Okumura A, Kurahashi H, Hirose S, et al. Focal epilepsy resulting from de novo SCN1A mutation.
Neuropediatrics 2007; 38: 253-6.
Patino GA, Claes LR, Lopez-Santiago LF, et al. A fuctional null mutation of SCN1B in a patient with
Dravet syndrome. J Neurosci 2009; 29: 2910764-78.
Pereira S, Vieira JP, Barroca F, et al. Severe epilepsy, retardation, and dysmorphic features with a 2q deletion including SCN1A and SCN2A. Neurology 2004; 63: 191-2.
Prunetti P, Perucca E. New and forthcoming antiepileptic drugs. Curr Opin Neurol 2011; 2: 159-64. Ragona F, Brazzo D, De Giorgi I, et al. Dravet syndrome: Early clinical manifestation and cognitive outcome in 37 Italian patients. Brain Dev 2010; 32: 71-7.
Ragona F, Granata T, Dalla Barnardina B, et al. Cognitive development in Dravet syndrome: A retrospective, multi center study of 26 patients. Epilepsia 2011; 52: 386-92.
Rodda JM, Scheffer IE, McMahom JM, Berkovic SF, Graham HK. Progressive Gait Deterioration in
Adolescents with Dravet Syndrome. Arch Neurol 2012; 69(7): 873-8.
Riva D, Vago C, Pantaleoni C, Bulgheroni S, Mantegazza M, Franceschetti S. Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes. Am J Med Genet Part A. 2009; 149a: 2339-45.
Saito Y, Oguni H, Awaya Y, Hayashi K, Osawa M. Phenytoin-induced choreoathetosis in patientis with severe myoclonic epilepsy in infancy. Neuropediatrics 2001; 32_ 231-5.
Sakauchi M, Oguni H, Kato I, et al. Mortality in Dravet syndrome: Search for risk factors in Japanase patients. Epilepsia 2011; 52 (Suppl. 2): 50-4.
Sarisjulis N, Gamboni B, Plouin P, Kaminska A, Dulac O. Diagnosis idiopathic/cryptogenic epilepsy syndromes in infancy. Arch Dis Child 2000; 82: 226-30.
Scheffer IE, Turner SJ, Dibbens LM, et al. Epilepsy and mental retardation limited to females: An under-recognized disorder. Brain 2008; 131: 918-27.
Scheffer IE. Diagnosis and long-term course of Dravet syndrome. European Journal of Paediatric Neurology 2012; 16: S5-S8.
Siegler Z, Barsi P, Neuwirth M, et al. Hippocampal sclerosis in seere myoclonic epilepsy in infancy: A retrospective MRI study. Epilepsia 2005; 46: 704-8.
Singh R, Andermann E, Whitehouse WP, et al. Severe myoclonic epilepsy of infancy: Extended spectrum of GEFS+? Epilepsia 2001; 42: 837-44.
Skluzacek JV, Watts KP, Parsy O, et al. Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 2011; 52 (Suppl. 2): 95-101.
Specchio N, Kasteleijn-Nost-Trenitè DGA, Piccioli M, et al. Diagnosing photosensitive epilepsy: Fancy new versus old fashioned techniques in patients with different epileptic sindrome. Brain Dev 2011; 33: 294-300.
Striano P, Mancardi MM, Biancheri R, et al. Brain MRI findings in severe myoclonic epilepsy in infancy and genotype-phenotype correlations. Epilepsia 2007a; 48: 1092-6.
Striano P, Coppola G, Pezella M, et al. An opel-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007b; 69: 922-5.
Suguma M, Oguni H, Fukuyama Y. Clinical and electroencephalographic study of severe myoclonic epilepsy in infancy (Dravet). Jpn J Psychiat Neurol 1987; 41: 463-5.
Suls A, Velizarova R, Yordanova I, et al.Four generations of epilepsy caused by an inherited microdeletion ofthe SCN1A gene. Neurology 2010; 75: 72-6.
Tanabè T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome): A nation-wide questionnaire survey in Japan. Brain Dev 2008; 30: 629-35.
Than TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tollerance of Stiripentol in severe myoclonic epilepsy of infancy (Dravet syndrome). Arch Pediatr 2002; 9: 1120-7.
Vadlamudi L, Dibbens LM, Lawrence KM, et al. Timing of the novo mutagenesis – a twin study of sodium-channel mutations. N Engl J Med 2010; 363: 1335-40.
Veggiotti P, Cardinalii S, Montalenti E, Gatti A, Lanzi G. Generalized epilepsy with febrile seizures plus and severe myoclonic epilepsy in infancy: A case report of two Italian families. Epileptic Disord 2001; 3: 29-32.
Villeneuve N, Portilla P, Ferrari AR, et al. Topiramate(TPM) in severe myoclonic epilepsy in infancy
(SMEI): Study of 27 patients. Epilepsia 2002; 43 (Suppl 8): 155.
Wakai S, Ito N, Sueoka H, et al. Severe myoclonic epilepsy in infancy and carbamazepine. Eur J Pediatr 1996b; 155: 724.
Wallace RH, Hodgson BL, Grinton BE, et al. Sodium channel alpha 1-subunit mutations in severe myoclonic epilepsy on infancy and infantile spasm. Neurology 2003; 61: 765-9.
Wang PJ, Fan PC, Lee WT, Young C, Huang CC, Shen YZ. Severe myoclonic epilepsy in infancy: evolution of electroencephalographic and clinical features. Acta Paed Sin 1996; 37: 428-32.
Wical B, Leighty D, Wendorf H, Tervo M, Tervo R, Maytum J. Signs of dysautonomia in children with Dravet syndrome (abstract). Epilepsia 2009; 50 (Suppl. 3): 164.
Yagi T, Takeichi M. Cadherin superfamily genes: Function, genomic organization, and neurologic diversity. Genes Dev 2000; 14: 1169-80.
Yakoub LM, Dulac O, Jambaqué I, Plouin P. Early diagnosis of severe myoclonic epilepsy in infancy.
Brain Dev 1992; 14: 299-303.
Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons un a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9: 1142-9.
Zaatreh M, Tennison M, D’Cruz O, Beach RL. Anticonvulsant-induced chorea: A role for pharmacodynamic drug interaction? Seizure 2001; 10: 596-9.
Zamponi N, Passamonti C, Cappanera S, Petrelli C. Clinical course of young patients with Dravet sindrome after vagal nerve stimulation. Eur J Ped Neurol 2010; 30: 1-7.
